HLS Therapeutics (TSE:HLS) Share Price Breaks Below 200 Day Moving Average – What’s Next?

HLS Therapeutics Inc. (TSE:HLS)’s stock price passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of C$4.31 and traded as low as C$4.20. HLS Therapeutics shares last traded at C$4.23, with a volume of 56,660 shares traded.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Canaccord Genuity Group raised shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 13th. Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from C$7.00 to C$8.00 in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy” and an average price target of C$8.00.

HLS Therapeutics Stock Down 5.4%

The company has a current ratio of 1.05, a quick ratio of 1.01 and a debt-to-equity ratio of 75.86. The company has a market capitalization of C$130.86 million, a price-to-earnings ratio of -15.67 and a beta of -0.52. The firm’s fifty day simple moving average is C$4.04 and its two-hundred day simple moving average is C$4.31.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share for the quarter. The firm had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative net margin of 15.26% and a negative return on equity of 14.39%. During the same period last year, the business posted ($0.09) earnings per share. Sell-side analysts anticipate that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.